Cancer News and Research

Latest Cancer News and Research

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

New research from Georgetown University Medical Center (GUMC) suggests that up to 40 percent of scleroderma patients will not be correctly diagnosed with the disorder using a new automated commercial screening test. The findings of the study will be presented Wednesday, November 10th at the Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia.

9 Nov 2010

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry [18:7966-7974, 2010] on the anticancer activity of quinoxalinyl-piperazine compounds.

9 Nov 2010

Only 50% of lung cancer patients in England are getting lifesaving surgery

Only half as many lung cancer patients in England are getting potentially lifesaving surgery compared to the best countries in the world, according to a new report by the National Cancer Intelligence Network (NCIN).

9 Nov 2010

Children with JIA face increase risk of developing cancer

Children with juvenile idiopathic arthritis have a two to threefold increased risk of developing cancer compared to similarly-aged children without JIA, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta. The same study also reported no cases of cancer in children with JIA who were exposed to anti-TNF therapy.

9 Nov 2010

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia

9 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

Mystic awarded $245,000 QTDP grant for VersiDoser Delivery Platform

Mystic Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of advanced precision ophthalmic and intranasal delivery technologies for drugs and biologics, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to its VersiDoser™ Delivery Platform under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

9 Nov 2010

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center.

9 Nov 2010

New guide predicts survival of terminally ill cancer patients

A new way of predicting how long terminally ill cancer patients have to live, has been devised by Cancer Research UK-funded research.

9 Nov 2010

S.A.N.E. Vax calls for federal approval of reliable HPV genotyping test in cervical cancer prevention programs

In a letter addressed to Dr. Harold E. Varmus, director of the NCI, and Dr. Margaret Hamburg, FDA commissioner, Ms. Norma Erickson, president of S.A.N.E. Vax, Inc., requested that these two federal agencies recommend a reliable human papillomavirus (HPV) genotyping test to support the national virology-based cervical cancer prevention program for patient care. Erickson stated: "The NCI knows reliable HPV genotyping is based on using a PCR system with short target sequencing."

9 Nov 2010

Research reveals body’s defence mechanism against snail fever

Scientists have made a significant discovery about how the body defends itself against snail fever, a parasitic worm infection common in developing countries.

9 Nov 2010

Gefitinib exhibits potential as chemoprevention agent for pancreatic cancer

Gefitinib may be a promising chemoprevention agent for pancreatic cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

9 Nov 2010

Study explains link between morbid obesity and metabolic syndrome

Scientists have found that the fat cells and tissues of morbidly obese people and animals can reach a limit in their ability to store fat appropriately. Beyond this limit several biological processes conspire to prevent further expansion of fat tissue and in the process may trigger other health problems.

9 Nov 2010

ORVACS launches ERAMUNE 01 Phase II study to decrease HIV viral reservoirs

ORVACS has launched a Phase II study designed to test the hypotheses that combination therapy with potent antiviral agents and immunomodulator can lead to a decrease in the HIV viral reservoirs and, ultimately, to eradication of the virus. The study is currently being conducted at clinical sites in France, Spain, Italy, and the United Kingdom.

9 Nov 2010

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL.

9 Nov 2010

Statistics show mesothelioma death rate has tripled in the last two decades

A leading north east industrial illness lawyer has today voiced 'serious concerns' about the number of people still dying after negligent exposure to asbestos and called for renewed efforts to secure justice for mesothelioma sufferers as new statistics show that the death rate has almost tripled in the last 20 years.

9 Nov 2010

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Inspiration Biopharmaceuticals, Inc. today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).

9 Nov 2010

Smoking increases risk of breast cancer progression in multiethnic women with breast cancer

Being a current smoker or having a history of smoking significantly increased the risk of breast cancer progression and overall death among a group of multiethnic women with breast cancer, according to the results of a large prospective cohort study.

9 Nov 2010

New approach to treat castration resistant prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

Genetic region linked to survival in patients with advanced bowel cancer

Scientists have discovered a genetic region linked to survival in patients with advanced bowel cancer, according to a study being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Tuesday).

9 Nov 2010